Calamos Advisors LLC Buys 634 Shares of Transcat, Inc. (NASDAQ:TRNS)

Calamos Advisors LLC raised its stake in Transcat, Inc. (NASDAQ:TRNS) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,281 shares of the scientific and technical instruments company’s stock after buying an additional 634 shares during the quarter. Calamos Advisors LLC’s holdings in Transcat were worth $1,015,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TRNS. US Bancorp DE raised its position in shares of Transcat by 137.9% in the 1st quarter. US Bancorp DE now owns 345 shares of the scientific and technical instruments company’s stock valued at $28,000 after acquiring an additional 200 shares during the period. BNP Paribas Arbitrage SA increased its stake in Transcat by 162.3% in the second quarter. BNP Paribas Arbitrage SA now owns 1,626 shares of the scientific and technical instruments company’s stock valued at $92,000 after purchasing an additional 1,006 shares in the last quarter. Barclays PLC raised its holdings in Transcat by 533.1% in the fourth quarter. Barclays PLC now owns 1,912 shares of the scientific and technical instruments company’s stock worth $135,000 after purchasing an additional 1,610 shares during the period. Legal & General Group Plc boosted its position in shares of Transcat by 219.9% during the fourth quarter. Legal & General Group Plc now owns 2,703 shares of the scientific and technical instruments company’s stock worth $192,000 after purchasing an additional 1,858 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in shares of Transcat by 1,157.4% in the 2nd quarter. Citigroup Inc. now owns 2,389 shares of the scientific and technical instruments company’s stock valued at $204,000 after buying an additional 2,199 shares during the period. Institutional investors own 98.34% of the company’s stock.

Transcat Price Performance

TRNS stock opened at $108.04 on Monday. The stock has a 50-day moving average price of $108.50 and a two-hundred day moving average price of $102.11. Transcat, Inc. has a 1 year low of $74.89 and a 1 year high of $115.41. The stock has a market cap of $953.99 million, a PE ratio of 83.11 and a beta of 0.59. The company has a current ratio of 3.37, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01.

Transcat (NASDAQ:TRNS) last released its quarterly earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.03. Transcat had a return on equity of 9.32% and a net margin of 4.16%. The firm had revenue of $65.17 million during the quarter, compared to the consensus estimate of $63.36 million. Equities analysts forecast that Transcat, Inc. will post 1.34 EPS for the current fiscal year.

Insider Buying and Selling

In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the sale, the chief executive officer now directly owns 108,478 shares in the company, valued at approximately $12,073,601.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Lee D. Rudow sold 2,373 shares of the company’s stock in a transaction that occurred on Saturday, March 30th. The stock was sold at an average price of $111.43, for a total transaction of $264,423.39. Following the sale, the chief executive officer now owns 103,688 shares in the company, valued at approximately $11,553,953.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Lee D. Rudow sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the transaction, the chief executive officer now directly owns 108,478 shares of the company’s stock, valued at $12,073,601.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,073 shares of company stock worth $900,023. 4.20% of the stock is owned by insiders.

Analysts Set New Price Targets

TRNS has been the topic of several research analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective (up previously from $120.00) on shares of Transcat in a research note on Thursday. TheStreet raised Transcat from a “c+” rating to a “b” rating in a research report on Wednesday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $124.00 price objective on shares of Transcat in a research report on Tuesday, April 16th.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.